tbuckley/cabot-search huggingface dataset:
Synovial sarcoma: Retrospective analysis of treatment outcome and prognostic factors
Authors: M. A. Memon, A. A. Allam, A. M. El-Enbaby, M. El-Sebaie, Y. M. Khafaga, H. Schultz, A. El-Weshi
Journal: Journal of Clinical Oncology (2007)

20517 Introduction and Objectives: Synovial Sarcoma (SS) account for approximately 10 % of soft tissue sarcoma. Despite numerous case reports and several relatively large series, debate still exists about the prognostic factors for this disease, the biologic behavior and role of adjuvant chemotherapy. The purpose of this study is to analyze the variable prognostic factors that may affect the treatment outcome in patients with SS. Patient and Methods: Sixty-six patients with SS (36 males and 30 females) were seen in institution between January 1985 and December 2000. Median age at diagnosis was 29 years. Site of involvement include, lower extremities 43/66 cases; (65%), upper extremity 16/66 (24%), trunk 3/66 (5%), others 4/66 (include larynx, thyroid, neck, and hypopharynx).Tumor size: = 10 cm 42/66 (64%), = 10 cm 24/66 (36%). Patients with stage III and IV disease represented 58% of all patients (38/66), stage I and II 42%(28/66). All patients underwent surgery and adequate resection margins(= 2 cm) were achieved in 52% of cases. Histopathology: Biphasic 36/66, Monophasic 16/66, spindle cell 12/66 and not otherwise specified 2/66. Radiation therapy was given 44/66 cases (67%). Chemotherapy was delivered to 11/66 patients (17%). Results: With a median follow up of 50 months, the 5-year overall survival (OS) for all patients was 45%, while the 5- year relapse free survival (RFS) for patients treated with radical intent was 32%. Prognostic factors that significantly affected OS on univariate analysis were tumor size (≤ 10 cm vs &gt; 10cm), tumor stage (stages I and II vs stage III), adequacy of surgical resection and local control. On multivariate analysis, tumor size and local control were the only independent factors that did affect OS. For RFS, sex, tumor size, tumor grade, tumor stage, and adequacy of surgical resection were the prognostic factors of significance on univariate. Tumor stage and sex were the only independent prognostic factors of significance on multivariate analysis for RFS. Conclusion: Tumor size, stage, grade, and adequacy of surgical resection are the main prognostic factors affecting OS and RFS. These parameters can help to identify the high risk patient who may qualify for aggressive treatment. No significant financial relationships to disclose.
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes
Authors: Wieneke A. Buikhuisen, Marion Scharpfenecker, Arjan W. Griffioen, Catharina M. Korse, Harm van Tinteren, Paul Baas
Journal: Journal of Thoracic Oncology (2016)
Immune Reactivity in Dogs With Spontaneous Malignancy 2 3
Authors: Paul L. Weiden, Rainer Storb, Hans-Jochem Kolb, Hans D. Ochs, Theodore C. Graham, Mang-So Tsoi, Maria-Louise Schroeder, E. Donnall Thomas
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Immune Reactivity in Dogs With Spontaneous Malignancy Get access Paul L. Weiden, M.D., Paul L. Weiden, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Rainer Storb, M.D., Rainer Storb, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Hans-Jochem Kolb, M.D., Hans-Jochem Kolb, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Hans D. Ochs, M.D., Hans D. Ochs, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Theodore C. Graham, Theodore C. Graham Search for other works by this author on: Oxford Academic PubMed Google Scholar Mang-So Tsoi, Ph.D., Mang-So Tsoi, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Maria-Louise Schroeder, M.D., Maria-Louise Schroeder, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar E. Donnall Thomas, M.D. E. Donnall Thomas, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 4, October 1974, Pages 1049–1056, https://doi.org/10.1093/jnci/53.4.1049 Published: 01 October 1974 Article history Received: 14 March 1974 Accepted: 02 July 1974 Published: 01 October 1974
Improved Reconstitution of CD4 T Cells and B Cells But Worsened Reconstitution of Serum IgG Levels After Allogeneic Transplantation of Blood Stem Cells Instead of Marrow
Authors: Jan Storek, Robert P. Witherspoon, David G. Maloney, Thomas R. Chauncey, Rainer Storb
Journal: Blood (1997)
A timing and process flow analysis of opening clinical trials within an oncology cooperative group setting: The case of the CALGB
Authors: D. M. Dilts, A. B. Sandler, M. Baker, S. Cheng, S. McGuire, G. Menon, A. Wu, K. Karas, D. Sawyer, R. L. Schilsky
Journal: Journal of Clinical Oncology (2006)

6015 Background: Cooperative oncology groups are major sponsors of Phase III clinical trials, yet the number of steps and times required to setup and open such a trial have yet to be studied. This study assesses these items in the Cancer and Leukemia Group B (CALGB) for all Phase III studies opened in a 3 year period. Methods: Step 1: headquarters and statistical center staff were interviewed to discover the detailed steps required for a study to transit from initial concept submission by a potential study chair to final activation of the study. The formal procedures manuals were also reviewed. All study records and draft protocol documents were inspected to verify and identify additional setup steps. Finally, data was collected through direct contact with study chairs and disease committee chairs. Step 2: timing data for each of the major functions or processes were collected. All times are from initial initiation of the function to the final completion of the task. Times represent calendar time. Step 3: creation of stream-lined process flows, currently underway. Members from the CALGB and the Vanderbilt Center for Management Research in Healthcare (cmrhc.org) will spend 2 days creating a process to significantly reduce the time and the number of steps to opening a trial. Results: A total of 13 Phase III studies were activated during the 3 years study period. 372 processes are required to open a Phase III at CALGB, which include 314 work steps, 43 major decision points. Interesting, most of the decision points (63%) are external to CALGB. There are 23 processing loops that require repeating processes. The process map, which lists all processes, is a chart 243.5” × 41 in 8 pt font (or about the length of a 20 passenger bus). Median calendar days to activate a Phase III study at CALGB is 767 days (min = 488, max = 1,441). The three functions requiring the greatest median days are protocol development (477), forms development (434), and regulatory affairs (350). Conclusion: It can require years to open a Phase III study at a major cooperative oncology group. Using process redesign techniques, we expect to be able to significantly streamline the process. Support provided by the NCI. No significant financial relationships to disclose.
Abstract 16090: Brown Adipose Tissue Transplantation Inhibits Atherosclerosis Development in Recipient Apoe Deficient Mice Without Affecting Glucose Homeostasis
Authors: Masakazu Kikai, Noriyuki Wakana, Daisuke Irie, Keita Yamamoto, Kensuke Terada, Hiroyuki Yamada
Journal: Circulation (2014)

BACKGROUND: Brown adipose tissue (BAT), a key nonshivering thermogenic tissue, has been recently identified as an endocrine organ to regulate glucose homeostasis as well as white adipose tissue. Experimental BAT transplantation has been shown to improve glucose tolerance and insulin sensitivity; however, the beneficial effect of BAT transplantation on atherogenesis remains undefined. METHOD AND RESULT: Interscapular BAT was removed from 12-week-old C57BL/6 mice and transplanted into the visceral cavity in 12-week-old recipient apoE-/- mice fed a high-cholesterol diet until 24 weeks of age. BAT transplanted mice showed a modest, but significant, decrease in body weight and increase in mean blood pressure as compared with those in sham control mice (4.7%, 12%, respectively, P<0.05). Lipid profile and food intake did not differ between the 2 groups of mice. Intraperitonial glucose tolerance test and insulin tolerance test performed at 24 weeks of age showed that BAT transplantation did not affect both glucos...
High efficacy of combination lamivudine and hepatitis B immunoglobulin in the prophylaxis of hepatitis B recurrence after liver transplantation.
Authors: P Ciccorossi, Franco Filipponi, F Oliveri, B Coco, P Colombatto, Ferruccio Bonino, Mario Campa, Franco Mosca, Maurizia Rossana Brunetto
Journal: Hepatology (2001)
TCT-261 Intra-aortic balloon pump therapy does not reduce mortality in acute myocardial infarction, with or without cardiogenic shock: application of a baseline inequality index to account for differential outcomes in randomized and observational studies
Authors: Yousif Ahmad, Sayan Sen, Matthew Shun-Shin, Graham Cole, Judith Finegold, Rasha Al-Lamee, Sukhjinder S. Nijjer, Ricardo Petraco, Christopher Cook, Iqbal S. Malik, Christopher S. Baker, Justin E. Davies, Jamil Mayet, Darrel P. Francis
Journal: Journal of the American College of Cardiology (2015)
Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer.
Authors: D. S. Mendelson, M. S. Gordon, L. S. Rosen, H. Hurwitz, M. K. Wong, B. J. Adams, D. Alvarez, B. K. Seon, C. P. Theuer, B. R. Leigh
Journal: Journal of Clinical Oncology (2010)

3013 Background: CD105 (endoglin) is an angiogenic membrane protein that is highly expressed on the proliferating vasculature of solid tumors and up-regulated following anti-VEGF therapy. TRC105 is a human/murine chimeric IgG1 anti-CD105 monoclonal antibody that inhibits angiogenesis and tumor growth via endothelial cell growth inhibition, ADCC, and apoptosis. Methods: The safety and PK of TRC105 were evaluated in pts with refractory cancer at dose levels from 0.01 to 1 mg/kg every 2 weeks using TRC105 produced in NS0 cells and then at 0.3 and 1 mg/kg using TRC105 with increased ADCC activity produced in a high-expressing CHO cell line. TRC105 was escalated in cohorts of 3-6 pts. Results: 33 ECOG PS 0-1 pts received TRC105 at doses between 0.01-1.0 mg/kg. Two dose-limiting toxicities (DLT) were reported in pts who received TRC105 produced in NS0 cells: one pt experienced grade 4 gastric ulcer bleeding at 0.1 mg/kg on day 4 which resolved spontaneously and one pt experienced grade 3 infusion reaction (without premedication). Infusion reactions were also noted in the initial two pts dosed at 0.3 mg/kg using TRC105 produced in CHO cells, including one grade 3 DLT. The protocol was amended to increase the infusion time from 1 to 4 hours and mandate premedication. Four pts were subsequently dosed at 0.3 mg/kg and six pts were dosed at 1 mg/kg without DLT following amendment. One pt with castrate- refractory prostate cancer remains on study after 20 months of TRC105 at 0.01 mg/kg with a complete PSA response and bone scan normalization. In addition, 6-month stable disease was seen in a pt with ovarian cancer (CA125 decrease of 16%). Best response also included stable disease > 2 months (n=9) and progression (n=18). Serum TRC105 concentrations expected to saturate CD105 binding sites (> 0.2 ug/mL) were achieved at a dose of 0.3 mg/kg, and concentrations > 10 ug/mL were achieved at 1.0 mg/kg. HAMA became detectable in 2 of 29 pts. Conclusions: TRC105 is tolerated at doses with evidence of clinical activity. Additional monotherapy and combination studies are planned. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration TRACON Pharma TRACON Pharma TRACON Pharma
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531
Authors: Jessica A. Pollard, Michael Loken, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Richard Aplenc, Irwin D. Bernstein, Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi
Journal: Journal of Clinical Oncology (2016)

CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level.CD33 expression levels were prospectively quantified by multidimensional flow cytometry in 825 patients enrolled in Children's Oncology Group AAML0531 and correlated with response to GO.Patients with low CD33 expression (lowest quartile of expression [Q1]) had no benefit with the addition of GO to conventional chemotherapy (relapse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456). However, patients with higher CD33 expression (Q2 to Q4) had significantly reduced RR (GO 32% v No-GO 49%, P < .001) and improved EFS (GO 53% v No-GO 41%, P = .005). This differential effect was observed in all risk groups. Specifically, low-risk (LR), intermediate-risk (IR), and high-risk (HR) patients with low CD33 expression had similar outcomes regardless of GO exposure, whereas the addition of GO to conventional chemotherapy resulted in a significant decrease in RR and disease-free survival (DFS) for patients with higher CD33 expression (LR RR, GO 13% v No-GO 35%, P = .001; LR DFS, GO 79% v No-GO 59%, P = .007; IR RR, GO 44% v No-GO 57%, P = .044; IR DFS, GO 51% v No-GO 40%, P = .078; HR RR, GO 40% v No-GO 73%, P = .016; HR DFS, GO 47% v No-GO 28%, P = .135).We demonstrate that GO lacks clinical benefit in patients with low CD33 expression but significantly reduces RR and improves EFS in patients with high CD33 expression, which suggests a role for CD33-targeted therapeutics in subsets of pediatric AML.
Interaction of Familial and Hormonal Risk Factors for Breast Cancer
Authors: L A Brinton, R Hoover, J F Fraumeni
Journal: JNCI Journal of the National Cancer Institute (1982)

A case-control study, conducted among participants in the Breast Cancer Detection Demonstration Project, obtained detailed information on family history of breast cancer and other risk factors from 1,362 breast cancer patients and 1,250 control subjects. An affected first-degree relative was reported by 22.4% of the patients and 12.2% of the control subjects. This finding was associated with a twofold increased risk of breast cancer, although greater elevations in risk were seen in younger study subjects and in those reporting both an affected mother and a sister. Analysis of other risk factors showed that, compared to women without a family history of breast cancer, control subjects with a family history of breast cancer tended to have early or late menarche, were older at first childbirth, and were younger at oophorectomy. In addition, the effect of family history on breast cancer risk was modified by age at menarche, but not by age at first birth or type of menopause. These findings suggest that familial susceptibility to breast cancer may be mediated through hormonal factors that operate early in a woman's life. A synergistic relationship was also observed between family history of breast cancer and the occurrence of multiple biopsies for benign breast disease, although the mechanisms for this relationship remain to be elucidated.
Confirmation of the prognostic value of the EORTC/WHO classification of primary cutaneous B-cell lymphoma in the United States: The Stanford University experience
Authors: S. A. Reddy, Y. H. Kim, R. H. Advani, R. T. Hoppe
Journal: Journal of Clinical Oncology (2007)

8028 Background: Primary cutaneous B cell lymphoma (CBCL) represent distinct clinicopathologic entities with superior prognosis compared to their nodal counterparts. In the new WHO/EORTC Classification of Cutaneous Lymphomas (WHOc), CBCL are classified as either Marginal Zone (MZ), Follicle center lymphoma (FC) or diffuse large cell-leg type (DLBCL leg-type). WHOc combined previous FL and DLBCL into the category of FC. Only DLBCL leg-type was considered to be aggressive and thus separately categorized. In order to confirm the utility of the WHOc categories, we reclassified our cases. Methods: Records of 154 CBCL patients (pts) managed at Stanford University were reviewed. A diagnosis of CBCL was made based on H&amp;E evaluation, immunohistochemistry including CD20 staining, along with a negative systemic staging evaluation. All pts were reclassified according to the WHO/EORTC classification of CBCL. Overall Survival (OS), disease specific survival (DSS) and freedom from progression (FFP) were analyzed according to the method of Kaplan and Meier. Prognostic factors were evaluated by multivariate regression model and included initial therapy, histology, LDH, stage, IPI, extent of disease and anatomic location. Results: 154 cases were reclassified as follows: 87 FC, 58 MZ, and 9 DLBCL leg-type. The median follow-up was 46 months. The 5 year OS and DSS were 86 and 95% respectively. For the MZ and FC subtypes the % 10 year OS/DSS was: 93/100, and 86/97 respectively. For DLBCL leg-type the % 5 year OS/DSS was 17/33 respectively. There were 22 deaths, seven of which were disease specific (4 DLBCL-leg type and 3 were FC). FFP was unaffected by the type of therapy given (chemotherapy or skin-directed). Conclusions: Our series is the largest single center experience in CBCL. We confirm the utility of the WHOc in distinguishing categories with differing prognosis. The indolent histologies have an excellent outcome and can be managed with local skin-directed therapy. The outcome of pt with DLBCL leg-type is significantly worse than the FC or MZ types and warrants a more aggressive approach in management. No significant financial relationships to disclose.
Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics
Authors: Brett D. McKinnon, Vida Kocbek, Kostantinos Nirgianakis, Nick A. Bersinger, Michael D. Mueller
Journal: Human Reproduction Update (2016)

BACKGROUNDEndometriosis, the growth of endometrial tissue outside the uterine cavity, is associated with chronic pelvic pain, subfertility and an increased risk of ovarian cancer. Current treatments include the surgical removal of the lesions or the induction of a hypoestrogenic state. However, a reappearance of the lesion after surgery is common and a hypoestrogenic state is less than optimal for women of reproductive age. Additional approaches are required. Endometriosis lesions exist in a unique microenvironment characterized by increased concentrations of hormones, inflammation, oxidative stress and iron. This environment influences cell survival through the binding of membrane receptors and a subsequent cascading activation of intracellular kinases that stimulate a cellular response. Many of these kinase signalling pathways are constitutively activated in endometriosis. These pathways are being investigated as therapeutic targets in other diseases and thus may also represent a target for endometriosis treatment.
Nadaplatin or cisplatin combined with paclitaxol in treating non-small cell lung cancer: A randomized controlled study
Authors: L. Chen, G. Xu, Z. Guan
Journal: Journal of Clinical Oncology (2007)

7689 Background: Nadaplatin is a 2nd generation platinum compound created in Japan. It also has been used in China for recent years and shown treatment effect in several kinds of cancer including lung cancer. However, no randomized clinical trial has been done compared with cisplatin when combined with paclitaxol in treating non-small cell lung cancer. This prospective clinical study is to investigate the treatment effect, long term survival, side effect and quality of life (QOL) of NSCLC patients treated with nadaplatin combined with paclitaxol controlled with cisplatin combined with paclitaxol. Methods: NSCLC patients with stage III B or IV were randomized into two groups: TN group- nadaplatin 30 mg/m 2 d1–3, paclitaxol 175 mg/m 2 d1, repeated every 4 weeks; TP group- DDP30 mg/m 2 d1–3, paclitaxol 175 mg/m 2 d1, repeated every 4 weeks. The treatment effect, 1 and 2 year survival and the side effect were observed. The functional assessment of cancer therapy-lung (FACT-L) was used to evaluate the quality of life (QOL). Results: Sixty patients were enrolled and 57 were assessable with 30 in TN group and 27 in TP group. The overall response rate were 43.3% vs 48.1% (P=0.716), and the disease control rate were 86.7% vs 88.8% in TN and TP group (P=0.799), respectively. The median survival time were 14.3 vs 13.0 months, and the 1 and 2 year survival were 62.5% vs 59.1%, 0% vs 5.8% in TN and TP group (P=0.839), respectively. Neutropenia and thrombocytopenia were similar in TN and TP group whereas more patients in TP group suffered from anemia (38.5% vs 17.5%, P=0.001), nausea and vomiting (68.0% vs 34.7% with grade 1 and 2, 14.6% vs 0.9% with grade 3 and 4, P=0.000), fatigue (35.9% vs 14.1% P=0.000) and peripheral neurotoxicity (50.0% vs 21.9%, calculated by case, p=0.023). In the FACT-L assessment, the relationship with doctor, the emotional well-being and the lung cancer related symptom were similarly improved in both TN and TP group whereas physical well-being was improved only in TN group. Conclusions: Nadaplatin combined with paclitaxol is an effective treatment regimen for NSCLC patients. When compared with similar regimen using cisplatin, the response rate and survival were similar; however, nadaplatin regimen shows superiority in some aspects of side effects and QOL. No significant financial relationships to disclose.
Melanoma in China: A prognostic study of 522 cases.
Authors: S. M. Li, J. Guo, Z. H. Chi, X. N. Sheng, L. Si, C. L. Cui, M. Han
Journal: Journal of Clinical Oncology (2010)

e19007 Background: There has been no epidemiological data of melanoma in China until now, even no large scale data in Asia. This study was performed to determine the characteristics and clinical outcome of patients with melanoma in China. Methods: Pts with melanoma came from 29 provinces of China since 2006 at Beijing cancer hospital were retrieved for this review. The medical records included age, gender, ulceration status, Breslow thickness, stage, primary site and histological type. Statistical analysis including survival and multivariate analysis of factors associated with survival were respectively performed by Kaplan-Meier method and Cox proportional hazard model by SPSS 11.0 software. Results: Of 522 cases could be evaluated. The male to female ratio was 1:0.89 and median age of diagnosis was 52 years (12-85 years). The incidence peak was from 45 to 55 years. There were 258 cases (49.4%) of acral lentiginous melanoma (ALM), 118 (22.6%) of mucosal melanoma (MCM), 69 (13.2%) of nodular melanoma (NM), 20 (3.8%) of superficial spreading melanoma (SSM), and others were unclassifiable. The proportion of pts with stage I, II, III and IV disease were respectively 6.1%, 55.9%, 25.1%, 12.8%. Ulceration status of 357 cases of cutaneous melanoma were recorded, 65.5% (234 pts) of them had ulceration. The 5-year survival rate of 522 pts was 41.6%, median survival time was 4.0 years (95%CI, 3.433-4.567). The difference in survival between MCM (5-y sur: 26.8%) and ALM (5-y sur: 53.9%) was significant (p = 0.003). Five-year survival rates of pts with and without ulceration were 43.3% and 70.4% (p = 0.078). Five-year survival rates of patients with stage I, II, III and IV disease were 94.4%, 44.8%, 40.2% and 5.1% respectively. Multivariate analysis showed stage III (HR = 9.682, p = 0.025) and IV (HR = 28.936, p = 0.001) correlated with worst prognosis, while other factors had no statistical correlation with survival. Conclusions: ALM and MCM are the common types of melanoma in China. Stage is the independent prognostic factors associated with survival. No significant financial relationships to disclose.